Home > Depression Treatment

Depression Treatment NYC: A Psychiatrist's Comprehensive Guide

By Ryan S. Sultan, MD
Assistant Professor of Clinical Psychiatry, Columbia University Irving Medical Center
Board-Certified in Adult Psychiatry and Child & Adolescent Psychiatry

What Is Depression? Understanding the Neurobiology

Depression is not simply "feeling sad." It is a medical condition rooted in brain chemistry, neural circuitry, and gene-environment interaction. When I explain depression to patients, I start with the biology because understanding what is happening in your brain removes the shame that keeps so many people from seeking help.

The brain regions most implicated in depression include the prefrontal cortex (responsible for executive function and emotional regulation), the amygdala (threat detection and emotional processing), the hippocampus (memory and context), and the anterior cingulate cortex (error monitoring and motivation). In depression, communication between these regions breaks down. The prefrontal cortex loses its ability to regulate the amygdala, which becomes hyperactive. The hippocampus literally shrinks -- MRI studies consistently show reduced hippocampal volume in people with recurrent depression.

The neurotransmitter story is more complex than "low serotonin." While serotonin dysfunction plays a role, depression involves disruption across multiple systems including norepinephrine, dopamine, glutamate, and GABA. More recent research points to neuroinflammation, HPA axis dysregulation (the stress response system), and impaired neuroplasticity -- the brain's ability to form new connections -- as central mechanisms. This is why no single medication works for everyone. The biology is heterogeneous, and treatment must be too.

Genetics contribute roughly 40% of depression risk. Having a first-degree relative with depression doubles or triples your own risk. But genes are not destiny. Epigenetic factors -- how life experiences modify gene expression -- play an equally important role. Early adversity, chronic stress, trauma, and social isolation can all alter gene expression in ways that increase vulnerability to depression.

Types of Depression: Not All Depression Is the Same

One of the most important things I do in an initial evaluation is determine what type of depression a patient has. This matters enormously for treatment selection. A patient with atypical depression responds differently to medication than someone with melancholic features. A patient with seasonal patterns needs a different approach than someone with treatment-resistant depression. Here are the major categories.

Major Depressive Disorder (MDD)

MDD is the most commonly diagnosed form of depression. The DSM-5 requires at least five of nine symptoms present for at least two weeks, with at least one being depressed mood or loss of interest/pleasure. The other symptoms include significant weight change, sleep disturbance (insomnia or hypersomnia), psychomotor agitation or retardation, fatigue, worthlessness or excessive guilt, difficulty concentrating, and recurrent thoughts of death.

What the diagnostic criteria don't capture is what MDD actually feels like: the morning dread, the inability to enjoy anything, the cognitive fog that makes simple decisions feel impossible, the physical heaviness in your limbs, the social withdrawal that feeds isolation which feeds more depression. The prevalence is staggering -- approximately 7% of U.S. adults in any given year, and 20% over a lifetime. Women are roughly twice as likely to be affected as men, though this may partly reflect diagnostic bias (men are more likely to present with irritability and substance use rather than classic sadness).

Persistent Depressive Disorder (Dysthymia)

Persistent Depressive Disorder (PDD), previously called dysthymia, is chronic depression lasting at least two years in adults (one year in adolescents). The symptoms are less severe than MDD but more persistent, creating a baseline of low mood that patients often describe as "just the way I am" or "my personality." This is particularly insidious because many people with PDD never seek treatment -- they have adapted to functioning at a diminished level and do not recognize that what they are experiencing is treatable.

PDD frequently co-occurs with episodes of major depression ("double depression"), which makes treatment more challenging. I see this pattern often in adults who have had untreated ADHD since childhood. Years of compensating for executive dysfunction, underperforming relative to potential, and accumulating negative feedback creates a chronic low-grade depression that they have internalized as an identity rather than a condition.

Seasonal Affective Disorder (SAD)

SAD follows a seasonal pattern, most commonly worsening in fall/winter and improving in spring/summer. It affects approximately 5% of the U.S. population, with higher rates in northern latitudes. The mechanism involves disrupted circadian rhythms, reduced serotonin synthesis from decreased sunlight exposure, and melatonin overproduction. Treatment includes light therapy (10,000 lux for 20-30 minutes each morning), SSRIs (particularly bupropion XL, which has FDA approval for SAD prevention), and behavioral activation.

In New York City, I see SAD frequently. The combination of short winter days, limited natural light in apartments, and the tendency to reduce physical activity in cold months creates a perfect storm. I typically recommend patients start light therapy and increase vitamin D supplementation in October before symptoms begin.

Postpartum Depression

Postpartum depression affects approximately 10-15% of new mothers and can onset during pregnancy or within the first year after delivery. It is distinct from the "baby blues" (transient mood lability in the first two weeks postpartum) in severity and duration. Symptoms include severe sadness, anxiety, difficulty bonding with the infant, intrusive thoughts about harming the baby, and significant functional impairment.

Hormonal shifts (particularly the rapid drop in estrogen and progesterone after delivery), sleep deprivation, and the stress of new parenthood all contribute. Risk factors include prior depression, ADHD (the executive demands of new parenthood are particularly overwhelming for people with ADHD), lack of social support, and complicated deliveries. Treatment involves psychotherapy, medication (certain SSRIs are compatible with breastfeeding), and -- in severe cases -- brexanolone (Zulresso), the first FDA-approved medication specifically for postpartum depression.

Treatment-Resistant Depression (TRD)

Treatment-resistant depression is formally defined as failure to achieve adequate response after two or more antidepressant trials of sufficient dose and duration. Approximately 30% of people with MDD meet criteria for TRD. This is an area of particular focus for me, given my training background.

During my psychiatry residency at Emory University, I trained under William McDonald, MD, one of the leading authorities on electroconvulsive therapy (ECT) and transcranial magnetic stimulation (TMS). I also worked closely with Pierpaolo Riva-Posse, MD, a pioneer in deep brain stimulation (DBS) for depression. That training gave me direct experience with the full spectrum of neuromodulation approaches and a deep appreciation for what is possible when medications are not enough.

But before labeling someone "treatment-resistant," I always ask: Was the diagnosis correct? Many cases of apparent TRD are actually undiagnosed bipolar disorder (which worsens with antidepressant monotherapy), untreated ADHD, thyroid dysfunction, sleep apnea, chronic pain, or substance use. A thorough re-evaluation frequently reveals a treatable factor that was missed. I have seen patients labeled treatment-resistant for years who responded rapidly once the correct comorbidity was identified and addressed.

ADHD and Depression: The Overlap I See Every Day

This is one of the areas where my expertise matters most. ADHD and depression are among the most commonly comorbid psychiatric conditions, and they are among the most commonly confused with each other. Getting this right changes lives.

How Common Is ADHD-Depression Comorbidity?

Why They Look Alike (and Why That Matters)

ADHD and depression share a striking number of overlapping symptoms: poor concentration, low motivation, fatigue, sleep disturbance, difficulty making decisions, irritability, and reduced productivity. A clinician who screens only for depression will find what they are looking for. I have treated many patients who spent years on antidepressants that helped their mood somewhat but never addressed the underlying attentional and executive dysfunction that was driving the mood problems in the first place.

The critical distinction is temporal pattern and mechanism. In ADHD, concentration problems are lifelong and context-dependent (better with high-interest tasks, worse with mundane ones). In depression, concentration problems represent a change from baseline and are pervasive. ADHD-related "low motivation" is actually a dopamine-mediated difficulty with task initiation rather than the anhedonia of depression. But when you have had untreated ADHD for 20 years, the chronic frustration, underachievement, and negative self-concept create genuine depression on top of the ADHD. Teasing apart what is primary and what is secondary requires experience with both conditions.

My Approach to ADHD-Depression Comorbidity

When I evaluate a patient presenting with depression who also has attentional complaints, I take a detailed developmental history. Did the concentration problems predate the mood symptoms? Were there academic or behavioral concerns in childhood? Is there a family history of ADHD? Do they have a pattern of starting projects with enthusiasm and then losing interest? Do they lose things, run late, struggle with organization in ways that are not fully explained by depression?

If ADHD is present, I typically address it first or simultaneously with the depression. Untreated ADHD is a potent driver of depression, and treating the ADHD alone sometimes resolves the depressive symptoms. When both require treatment, I use strategic medication combinations. Bupropion (Wellbutrin) is often a good choice because it has evidence for both depression and ADHD. Stimulant medications can have mood-elevating effects in patients with ADHD. I avoid medications that worsen executive function (certain antihistaminic antidepressants) and monitor carefully for emotional blunting from SSRIs, which can be particularly problematic in ADHD patients.

For a deeper dive into ADHD, see my comprehensive ADHD guide.

Depression in Adolescents: What Parents Need to Know

As a board-certified child and adolescent psychiatrist, I treat depression across the lifespan, and adolescent depression requires a fundamentally different approach than adult depression. Adolescent brains are still developing -- particularly the prefrontal cortex, which is not fully mature until the mid-20s. This means adolescents have less capacity for emotional regulation, are more susceptible to peer influence, and are more vulnerable to the neurobiological effects of depression on brain development.

How Adolescent Depression Looks Different

Adolescent depression often does not look like adult depression. Instead of pervasive sadness, the predominant mood may be irritability. Adolescents with depression frequently present as angry, oppositional, or defiant rather than weepy or withdrawn. Other presentations include:

• Academic decline -- grades dropping, loss of motivation for school, not turning in assignments
• Social withdrawal -- pulling away from friends, spending excessive time alone in their room
• Somatic complaints -- headaches, stomachaches, fatigue that has no medical explanation
• Sleep changes -- sleeping excessively (hypersomnia is more common in teens than insomnia)
• Substance use -- self-medicating with cannabis, alcohol, or other substances
• Risk-taking behavior -- recklessness, sexual risk, confrontational behavior
• Self-harm -- cutting, burning, or other non-suicidal self-injury

The biggest danger is dismissing these signs as "normal teenage behavior." While some moodiness is developmentally normal, persistent functional impairment is not. The average delay between depression onset and treatment in adolescents is 6-8 years. That is 6-8 years of impaired social development, academic underperformance, and increasing suicide risk.

Treatment Considerations for Adolescents

The evidence base for adolescent depression treatment supports psychotherapy as first-line for mild to moderate cases, with medication added for moderate to severe presentations. Cognitive Behavioral Therapy (CBT) and Interpersonal Therapy for Adolescents (IPT-A) have the strongest evidence. Among medications, fluoxetine (Prozac) has the most robust evidence base in adolescents and is the only SSRI FDA-approved for pediatric depression. Escitalopram (Lexapro) is approved for adolescents ages 12 and older.

The FDA black box warning about suicidality in youth treated with antidepressants requires context. The absolute risk increase is small (from 2% to 4% for suicidal ideation), and the risk of untreated depression -- including completed suicide -- is far greater. The black box warning, while well-intentioned, has paradoxically contributed to undertreatment of adolescent depression and may have increased suicide rates by discouraging appropriate prescribing. The key is close monitoring, particularly in the first 4-8 weeks of treatment, and open communication with the adolescent and family.

Cannabis use in depressed adolescents deserves special mention. My NIH-funded research examines how cannabis affects the developing adolescent brain. Many depressed teens self-medicate with cannabis, which can provide temporary mood relief but worsens depression over time, impairs cognitive development, and increases the risk of psychosis in genetically vulnerable individuals. I address substance use directly as part of any adolescent depression treatment plan.

Treatment-Resistant Depression: When Standard Approaches Are Not Enough

Approximately one-third of people with depression do not respond adequately to first-line treatments. This is where clinical expertise and training in advanced modalities becomes critical. My residency at Emory gave me exposure to the full range of interventions for treatment-resistant depression in a way that few training programs offer.

Ruling Out Misdiagnosis First

Before pursuing advanced treatments for TRD, I conduct a systematic review of potential confounders:

• Bipolar disorder -- Unipolar depression and bipolar depression look identical during depressive episodes. Antidepressant monotherapy in bipolar disorder can cause cycling, mixed states, and apparent treatment resistance. I screen carefully for any history of hypomanic or manic episodes, family history of bipolar disorder, and antidepressant-induced activation.
• Undiagnosed ADHD -- As discussed above, untreated ADHD drives chronic depression that will not fully resolve with antidepressants alone.
• Thyroid dysfunction -- Hypothyroidism produces depression symptoms that mimic MDD. Even subclinical hypothyroidism (TSH in the upper-normal range) can contribute. I check a full thyroid panel.
• Sleep apnea -- Untreated sleep apnea causes fatigue, cognitive impairment, and mood disturbance that is indistinguishable from depression. I refer for sleep studies when indicated.
• Substance use -- Alcohol and benzodiazepine use directly cause and perpetuate depression. Ongoing substance use undermines antidepressant efficacy.
• Medication non-adherence -- Studies consistently show that 50% of psychiatric patients do not take medications as prescribed. I assess adherence directly.
• Inadequate prior trials -- Many "failed" antidepressant trials were actually inadequate in dose, duration, or both. I review the exact medications, doses, and durations before concluding a medication failed.

Neuromodulation: TMS and ECT

When medications and therapy are insufficient, neuromodulation offers evidence-based alternatives that directly target brain circuits.

Transcranial Magnetic Stimulation (TMS) uses focused magnetic fields to stimulate the left dorsolateral prefrontal cortex (DLPFC), a region consistently hypoactive in depression. Standard TMS involves 30-36 sessions over 6-9 weeks. The FDA-cleared protocol produces response rates of 50-60% and remission rates of approximately 30% in treatment-resistant patients. The newer Stanford Neuromodulation Therapy (SNT) protocol -- an accelerated form of intermittent theta burst stimulation delivered over 5 days -- showed an 80% remission rate in its initial trial, though real-world effectiveness is still being established. TMS is non-invasive, does not require anesthesia, and patients can drive themselves to and from sessions.

Electroconvulsive Therapy (ECT) remains the most effective treatment for severe, treatment-resistant depression, with remission rates of 50-70%. Despite its reputation, modern ECT bears little resemblance to its historical portrayal. It is performed under general anesthesia with muscle relaxation, and the actual seizure is brief and controlled. I trained extensively in ECT under William McDonald at Emory, who has published some of the most important work on ECT techniques and outcomes. The main limitation is cognitive side effects, particularly anterograde and retrograde amnesia, which are usually temporary but can be persistent in some patients. Ultra-brief pulse techniques have reduced cognitive side effects while maintaining efficacy.

My colleague at Emory, Pierpaolo Riva-Posse, MD, is one of the leading researchers in deep brain stimulation (DBS) for depression -- an experimental approach that involves implanting electrodes in specific brain regions. While DBS for depression is still investigational, the research has advanced our understanding of depression circuitry enormously and points toward increasingly targeted neuromodulation approaches in the future.

Ketamine and Esketamine: The Rapid-Acting Revolution

Ketamine represents one of the most significant advances in depression treatment in decades. I have been involved with ketamine research since my time at Emory, where I co-authored a 2014 paper in Psychosomatics examining ketamine in the context of electroconvulsive therapy. That work connected me with John Krystal, MD, Chair of Psychiatry at Yale and one of the pioneers of ketamine research for mood disorders.

How Ketamine Works

Traditional antidepressants target monoamine systems (serotonin, norepinephrine, dopamine) and take 4-8 weeks to produce full effects. Ketamine works through an entirely different mechanism -- the glutamate system. Glutamate is the brain's primary excitatory neurotransmitter, and ketamine's blockade of NMDA receptors triggers a cascade of downstream effects:

• Rapid synaptogenesis -- New synaptic connections form within hours, reversing the synaptic atrophy caused by chronic stress and depression
• BDNF release -- Brain-derived neurotrophic factor, a critical growth factor for neural plasticity, increases rapidly
• mTOR pathway activation -- This intracellular signaling pathway promotes protein synthesis needed for new synapse formation
• AMPA receptor potentiation -- Enhanced glutamatergic signaling through AMPA receptors contributes to the antidepressant effect
• Anti-inflammatory effects -- Ketamine reduces neuroinflammation, which is increasingly recognized as a contributor to depression

The clinical result is dramatic: patients with severe, treatment-resistant depression can experience significant mood improvement within hours to days rather than weeks. I have seen patients who were suicidal on Monday report meaningful relief by Wednesday. This speed of action is unprecedented in psychiatry.

IV Ketamine vs. Esketamine (Spravato)

Both forms require monitoring during and after administration (typically 2 hours) due to dissociative effects, blood pressure elevation, and sedation. Patients cannot drive after treatment. Side effects are generally well-tolerated and transient. The main limitation is durability -- ketamine's antidepressant effects typically last days to weeks, requiring ongoing maintenance treatments.

The question of who is the ideal candidate for ketamine is important. I consider ketamine for patients who have failed two or more adequate antidepressant trials, patients with acute suicidality who need rapid relief, and patients who cannot tolerate standard antidepressants. I also use ketamine as a bridge -- providing rapid symptom relief while slower-acting treatments (medications, therapy) take effect.

Evidence-Based Treatments: The Full Toolkit

Medications for Depression

Medication selection for depression should be systematic, not trial-and-error. I consider the patient's symptom profile, comorbidities, prior medication history, family medication history (if a relative responded to a specific medication, the patient is more likely to as well), potential side effects, and drug interactions.

SSRIs (Selective Serotonin Reuptake Inhibitors) remain first-line for most patients. Fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), and paroxetine (Paxil) have the strongest evidence base. They are generally well-tolerated, safe in overdose, and effective for comorbid anxiety. Common side effects include sexual dysfunction (30-40%), weight gain, GI disturbance, and emotional blunting. Onset of action is typically 4-6 weeks.

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors) including venlafaxine (Effexor) and duloxetine (Cymbalta) add norepinephrine reuptake inhibition to serotonin effects. They are particularly useful for depression with prominent fatigue, pain syndromes, or when SSRIs have been insufficient. Venlafaxine at higher doses may have slightly higher efficacy than SSRIs for severe depression. Side effects include those of SSRIs plus blood pressure elevation (particularly with venlafaxine) and a more difficult discontinuation syndrome.

Atypical Antidepressants include bupropion (Wellbutrin), mirtazapine (Remeron), and trazodone. Bupropion works through norepinephrine and dopamine, making it an excellent choice for patients with comorbid ADHD, those concerned about sexual side effects, or those who need an activating medication. It does not cause weight gain and may actually reduce weight. Mirtazapine is useful for depression with insomnia, poor appetite, and anxiety -- its sedating and appetite-stimulating effects can be therapeutic. Trazodone is primarily used for insomnia at low doses but has antidepressant effects at higher doses.

Tricyclic Antidepressants (TCAs) such as nortriptyline, amitriptyline, and desipramine are older medications that remain effective, particularly for severe or treatment-resistant depression. They are also useful for comorbid pain conditions and insomnia. Their side effect profile (anticholinergic effects, cardiac conduction changes, lethality in overdose) limits first-line use, but they should not be forgotten as options when newer medications fail.

MAOIs (Monoamine Oxidase Inhibitors) including phenelzine (Nardil) and tranylcypromine (Parnate) are the most effective class of antidepressants for atypical depression (features of increased appetite, hypersomnia, leaden paralysis, and rejection sensitivity). They are underused due to dietary restrictions (tyramine avoidance) and drug interactions, but in the right patient, they are transformative. The selegiline transdermal patch (Emsam) at the lowest dose bypasses dietary restrictions and provides a more convenient MAOI option.

Augmentation Strategies for partial responders include adding atypical antipsychotics (aripiprazole/Abilify, quetiapine/Seroquel, brexpiprazole/Rexulti -- all FDA-approved as adjuncts), lithium, thyroid hormone (T3), or buspirone. Augmentation is typically more effective than switching when a patient has had a partial response to an antidepressant.

Psychotherapy for Depression

Medication without therapy is often incomplete treatment. The research is clear: the combination of medication and psychotherapy produces better outcomes than either alone. At Integrative Psych, I integrate evidence-based therapy approaches with pharmacological management.

Cognitive Behavioral Therapy (CBT) has the most extensive evidence base for depression treatment. CBT identifies and challenges distorted thinking patterns (cognitive distortions) and modifies maladaptive behaviors (behavioral activation). A typical course is 12-20 sessions. Meta-analyses show CBT is as effective as antidepressants for mild to moderate depression and reduces relapse rates when used as maintenance. For patients with comorbid ADHD, I adapt CBT to address executive function challenges that can undermine standard CBT protocols.

Interpersonal Therapy (IPT) focuses on improving interpersonal functioning and social support. It addresses four problem areas: grief, role transitions, role disputes, and interpersonal deficits. IPT is particularly effective for depression triggered by relationship problems, losses, or major life changes. It has strong evidence in both adults and adolescents (IPT-A).

Psychodynamic Therapy explores how unconscious patterns, early experiences, and relationship dynamics contribute to depression. Short-term psychodynamic therapy (16-24 sessions) has growing evidence for depression and may be particularly helpful for patients whose depression is driven by character pathology, attachment issues, or chronic interpersonal difficulties.

Behavioral Activation (BA) focuses specifically on increasing engagement with rewarding activities and reducing avoidance behaviors. It is a component of CBT but can be delivered as a standalone treatment. BA is particularly useful for patients with prominent anhedonia and social withdrawal. Its simplicity makes it accessible even for patients with significant cognitive impairment from depression.

Mindfulness-Based Cognitive Therapy (MBCT) combines mindfulness meditation practices with cognitive therapy techniques. It has the strongest evidence as a relapse prevention strategy for patients with three or more prior depressive episodes, where it reduces relapse rates by approximately 50%.

How I Approach Depression at Integrative Psych

My approach to depression treatment at Integrative Psych reflects both my academic training and clinical experience. It is integrative not in the vague wellness-industry sense, but in the evidence-based sense: I integrate medication management, psychotherapy, lifestyle interventions, and -- when needed -- neuromodulation into a coherent treatment plan tailored to the individual.

The Initial Evaluation

A thorough depression evaluation takes 60-90 minutes and covers:

• Detailed symptom assessment -- Current symptoms, onset, duration, severity, triggers, and pattern. I use the PHQ-9 as a baseline severity measure.
• Diagnostic clarification -- Screening for bipolar disorder, ADHD, anxiety disorders, PTSD, OCD, and personality disorders that may be causing or complicating the presentation.
• Medical evaluation -- Review of medical history, current medications, and relevant labs (thyroid function, metabolic panel, vitamin D, B12, folate, CBC). Medical conditions that mimic depression must be ruled out.
• Substance use assessment -- Alcohol, cannabis, stimulants, opioids, and other substances. I assess this directly and without judgment -- substance use and depression frequently co-occur, and both must be addressed.
• Developmental and family history -- Childhood experiences, trauma, family psychiatric history. This helps determine depression subtype and guide treatment selection.
• Prior treatment history -- Every medication tried, at what dose, for how long, with what response and side effects. Every therapy tried, with whom, what type, and for how long. This information is essential for avoiding repeating failed approaches and building on partial successes.
• Safety assessment -- Suicidal ideation, self-harm, access to lethal means. This is assessed at every visit, not just the first.
• Functional assessment -- Impact on work, relationships, self-care, and daily functioning. This determines treatment urgency and intensity.

Treatment Planning

Based on the evaluation, I develop a treatment plan that typically includes:

Lifestyle Interventions I Actually Prescribe

These are not afterthoughts or generic advice. They are evidence-based interventions I prescribe with the same specificity as medications:

• Exercise -- 150 minutes per week of moderate aerobic exercise has an antidepressant effect size comparable to medication for mild to moderate depression. I prescribe specific exercise targets and follow up on adherence.
• Sleep optimization -- Depression disrupts sleep, and disrupted sleep worsens depression. I address sleep architecture directly: consistent sleep-wake times, no screens 60 minutes before bed, no caffeine after noon, dark and cool bedroom, no alcohol (it fragments sleep despite feeling sedating).
• Social engagement -- Depression drives isolation, isolation worsens depression. I assign social activities as behavioral prescriptions.
• Dietary modification -- The Mediterranean diet has prospective evidence for depression prevention and treatment. Reducing processed food, increasing omega-3 fatty acids, and ensuring adequate folate, vitamin D, and B12 supports treatment response.
• Substance reduction -- Alcohol cessation or significant reduction, cannabis reduction, and elimination of recreational drug use. These are not optional lifestyle suggestions -- they directly impact treatment efficacy.

Depression and Substance Use: What the Research Shows

My research at Columbia focuses on the intersection of substance use and mental health, and substance use in the context of depression is an area where I bring both research expertise and clinical perspective.

Alcohol and Depression

Alcohol is a central nervous system depressant that disrupts serotonin function, impairs sleep architecture, and increases cortisol levels. The relationship with depression is bidirectional: depression increases the risk of alcohol use disorder by 2-3x, and alcohol use disorder increases depression risk by a similar magnitude. Approximately 30-40% of people with alcohol use disorder have comorbid depression.

The clinical challenge is that alcohol provides temporary mood relief through GABA-mediated anxiolysis and dopamine release, reinforcing continued use. But the net effect is profoundly depressive. I have had many patients whose "treatment-resistant depression" resolved within 4-6 weeks of alcohol cessation. This is not a popular message, but it is supported by the data.

Cannabis and Depression

Cannabis and depression have a complex relationship that is particularly relevant given my NIH-funded cannabis research. Many people use cannabis to self-medicate depressive symptoms, and low-dose THC may provide transient mood improvement. However, chronic cannabis use is associated with amotivational symptoms, impaired cognitive function, and -- in adolescents -- disrupted brain development in regions critical for mood regulation.

The data is especially concerning for adolescents. Regular cannabis use during adolescence is associated with a 37% increased risk of developing depression in adulthood (Lancet Psychiatry, 2019). For adolescents already experiencing depression, cannabis use complicates treatment, reduces medication adherence, and can trigger psychotic symptoms in genetically vulnerable individuals. I address cannabis use directly and non-judgmentally in every adolescent depression evaluation.

When to Seek Help for Depression

Depression is one of the most treatable conditions in psychiatry. The majority of people respond to appropriate treatment. The biggest obstacle is not the disorder itself -- it is the delay in seeking help. The average time from symptom onset to treatment is 6-8 years. That represents years of unnecessary suffering, impaired relationships, career underperformance, and accumulated negative effects on brain structure and function.

If you recognize yourself in any of the descriptions above -- whether it is the persistent low mood of MDD, the chronic flatness of dysthymia, the seasonal patterns, the overlap with ADHD, or the use of substances to cope -- reach out. Depression is not something you need to push through or will yourself out of. It is a medical condition, and medical conditions deserve medical treatment.

What to Expect in a Depression Evaluation

Many people delay seeking help because they do not know what to expect. Here is what an evaluation looks like in my practice:

Before the appointment: You will complete intake forms covering your symptoms, medical history, medications, and family history. This saves time during the session and allows me to review your information beforehand.

During the appointment (60-90 minutes): We will have a conversation -- not a checklist. I will ask about your current symptoms, their onset and course, your life context, prior treatments, and what you are hoping to achieve. I will screen for conditions that commonly co-occur with or mimic depression (ADHD, bipolar disorder, anxiety, substance use, medical conditions). I will ask about suicidal thoughts directly -- this is standard clinical practice and not something to be alarmed about.

After the appointment: You will leave with a diagnostic formulation (my clinical understanding of what is happening), a treatment plan (medication, therapy, lifestyle, or some combination), and a clear timeline for follow-up. I believe in collaborative decision-making -- you will understand why I am recommending what I am recommending, and your preferences matter in treatment selection.

Follow-up: Initial follow-up appointments are typically scheduled every 2-4 weeks to monitor response, adjust medications, and address side effects. Once stable, appointments may move to monthly or quarterly. I use standardized rating scales (PHQ-9) at each visit to track progress objectively.

Depression FAQs

What are the different types of depression?
The main types include Major Depressive Disorder (MDD), Persistent Depressive Disorder (dysthymia), Seasonal Affective Disorder (SAD), Postpartum Depression, and Treatment-Resistant Depression (TRD). Each has distinct features, duration, and treatment approaches.

How are ADHD and depression related?
ADHD and depression frequently co-occur, with 30-50% of adults with ADHD also experiencing depression. The two conditions share overlapping symptoms like poor concentration and low motivation, leading to frequent misdiagnosis. Untreated ADHD often causes secondary depression through chronic underperformance and frustration. Proper diagnosis requires a clinician experienced with both conditions.

What is treatment-resistant depression?
Treatment-resistant depression (TRD) is defined as failure to achieve remission after two or more adequate antidepressant trials. About 30% of people with depression fall into this category. Options include medication augmentation, neuromodulation (TMS, ECT), ketamine/esketamine, and combined therapy approaches. Many cases of apparent TRD involve missed diagnoses such as bipolar disorder or ADHD.

How does ketamine treat depression?
Ketamine works through the glutamate system, producing rapid antidepressant effects within hours to days. It promotes new synaptic connections and neural plasticity. Both IV ketamine and intranasal esketamine (Spravato) are used for treatment-resistant depression. Effects require maintenance treatments for sustained benefit.

Can depression affect teenagers differently than adults?
Yes. Adolescent depression often presents as irritability rather than sadness, along with academic decline, social withdrawal, somatic complaints, and risk-taking behavior. Treatment involves psychotherapy (CBT, IPT-A) and medication when warranted, with careful monitoring. Early intervention is critical for developmental outcomes.

When should someone seek help for depression?
Seek evaluation when depressive symptoms persist for more than two weeks and interfere with daily functioning. Immediate evaluation is needed for suicidal thoughts, self-harm, inability to perform basic self-care, or using substances to cope with mood. Early treatment produces better outcomes.

What role does substance use play in depression?
Depression and substance use disorders frequently co-occur and worsen each other. Alcohol directly causes and perpetuates depression. Cannabis may provide temporary relief but worsens depression with chronic use and impairs adolescent brain development. Effective treatment addresses both conditions simultaneously.

What should I expect during a depression evaluation?
A thorough evaluation takes 60-90 minutes and includes detailed symptom assessment, screening for comorbid conditions, medical history review, substance use assessment, safety evaluation, and collaborative treatment planning. You will leave with a diagnostic formulation and a clear plan.

Further Reading

• Comprehensive ADHD Guide -- Understanding ADHD-depression comorbidity
• Integrative Psych NYC -- Our approach to psychiatric care
• Cannabis and Mental Health -- Research on cannabis and mood disorders
• ADHD Burnout -- When ADHD exhaustion mimics depression
• Rejection Sensitive Dysphoria -- The emotional component of ADHD
• Evolutionary Psychiatry -- Why depression persists from an evolutionary perspective
• ADHD vs. Anxiety -- Differentiating overlapping symptoms